ClinicalTrials.gg
CompletedNCT01052077STEP-D222Updated Nov 2, 2015Results posted

Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder

A Phase 2 interventional study of OPC-34712 and Placebo in Major Depressive Disorder, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 43 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2015-11-02.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
773
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 24 studies testing brexpiprazole in Depressive Disorder, Major — 1 open to participants now, 1 under way, none of them phase 3. brexpiprazole · Depressive Disorder, Major.

Enrollment
9th of 24
773 · median 189
Started
2010
the only one that year
Phase 2
3 of 24
none open now
Registered
2nd of 24
by date
Lead sponsor
15 of 24
Otsuka Pharmaceutical Development & Commercialization, Inc.

Among the 24 studies testing brexpiprazole in Depressive Disorder, Major, this one is the 9th largest by enrollment, is the only one that started in 2010, is one of 3 in phase 2, and was the 2nd registered.

Depressive Disorder, Major

3,050 studies on the registry are indexed under Depressive Disorder, Major; 594 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

1 of the 24 studies testing brexpiprazole in Depressive Disorder, Major is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About brexpiprazole

brexpiprazole: first FDA approval 2015 (REXULTI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 297 (71%) stop at 75 or younger; 55 take children under 18; 100 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies testing brexpiprazole in Depressive Disorder, Major, or all of them as a file.
02

Study summary

This is a Double-blind study wherein patients with Major Depressive Disorder (MDD) will receive either from 1 to 3 mg a day of study medication (OPC-34712)or placebo (an inactive substance) in addition to an FDA approved antidepressant in order to determine if the study medication is effective as an add on treatment of MDD.

03

Conditions studied

  • Major Depressive Disorder

Keywords

  • OPC-34712
  • Major Depressive Disorder
  • Adjunctive Treatment
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subjects between 18 and 65 years of age, with diagnosis of major depressive disorder, as defined by criteria
  • The current depressive episode must be equal to or greater than 8 weeks in duration
  • Subjects must report a history for the current depressive episode of an inadequate response to at least one and no more than three adequate antidepressant treatments.

Exclusion criteria

Exclusion Criteria:

  • Females who are breast-feeding and/or who have a positive pregnancy test result prior to receiving study drug.
  • Subjects who report an inadequate response to more than three adequate trials of antidepressant treatments during current depressive episode at a therapeutic dose for an adequate duration.
  • Subjects with a current Axis I () diagnosis of: Delirium, dementia,amnestic or other cognitive disorder Schizophrenia, schizoaffective disorder, or other psychotic disorder Bipolar I or II disorder
  • Subjects with a current Axis II (DSM-IV-TR) diagnosis of borderline, antisocial, paranoid, schizoid, schizotypal or histrionic personality disorder.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
773 participants (actual)

Study arms

  • Experimental
    Brexipiprazole + ADT

    OPC-34712 Tablets, Oral, 1 - 3 mg OPC-34712 + ADT

    Drug: OPC-34712 · Drug: Placebo · Drug: ADT

  • Placebo comparator
    Placebo + ADT

    Placebo + ADT

    Drug: Placebo · Drug: ADT

Interventions

06

What researchers measure

Primary outcomes

  1. Change From the End of Phase A (Week 8 Visit) to the End of Phase B (Week 14 Visit) in the Montgomery Asberg Depression Rating Scale (MADRS) Total Score.

    The MADRS was utilized as the primary efficacy assessment of a participants level of depression. The MADRS consisted of 10 items, all rated on a 0 to 6 scale with 0 being the "best" rating and 6 being the "worst" rating. The MADRS Total Score is the sum of ratings for all 10 items; therefore, possible total scores range from 0 to 60. The MADRS total score were to be unevaluable if less than 8 of the 10 items were recorded. If 8 or 9 of the 10 items were recorded, the MADRS total score was the mean of the recorded items multiplied by 10 and then rounded of to the first decimal place.

    Time frame: Baseline (end of week 8) to Week 14

Secondary outcomes

  1. Change From End of Phase A (Week 8) to Phase B in Sheehan Disability Scale (SDS) Score.

    The SDS was a self-rated instrument used to measure the effect of the participants symptoms on work/school, social life, and family/home responsibilities. For each of the three items, scores ranged from 0 through 10. The number most representative of how much each area was disrupted by symptoms was marked along the line from 0= not at all, to 10= extremely. Scores of 5 and above are associated with significant functional impairment. The SDS total score ranges from 0 to 30, with higher values indicating greater disruption in the participant's work/social/family life. For the work/school item, no response was to be entered if the participant did not work or go to school for reasons unrelated to the disorder and a response therefore not being applicable. The Mean SDS score were calculated over the three item scores. All three item scores were needed to be available with the exception of the work/school item score when this item was not applicable.

    Time frame: Baseline (end of week 8) to Week 14

  2. Change From End of Phase A (Week 8 Visit) in MADRS Total Score for Every Trial Week Visit in Phase B.

    The MADRS was utilized as the primary efficacy assessment of a participants level of depression. The MADRS consisted of 10 items, all rated on a 0 to 6 scale with 0 being the "best" rating and 6 being the "worst" rating. The MADRS Total Score is the sum of ratings for all 10 items; therefore, possible total scores range from 0 to 60. The MADRS total score were to be unevaluable if less than 8 of the 10 items were recorded. If 8 or 9 of the 10 items were recorded, the MADRS total score was the mean of the recorded items multiplied by 10 and then rounded of to the first decimal place.

    Time frame: Baseline (end of week 8) to Week 14

  3. Change From End of Phase A (Week 8 Visit) to Phase B by Study Week in Clinical Global Impression- Severity Illness Scale (CGI-S) Score.

    The severity of illness for each participant was rated using the CGI-S. To perform this assessment, the investigator had to answer the following question: "Considering your total clinical experience with this particular population, how mentally ill is the participant at this time?" Response choices included: 0 = not assessed; 1 = normal, not at all ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill participants.

    Time frame: Baseline (end of week 8) to Week 14

  4. Change From End of Phase A (Week 8 Visit) to Phase B by Study Week in Inventory of Depressive Symptomatology (Self-Report) (IDS-SR) Total Score.

    The IDS-SR was a 30-item self-report measure, that was used to assess core diagnostic depressive symptoms as well as atypical and melancholic symptom features of major depressive disorder (MDD). For individual items, the scores range from 0 to 3. The IDS-SR are scored by summing responses to 28 of the 30 items to obtain a total score ranging from 0 to 84, higher values indicate greater disruption in the depressive symptoms.

    Time frame: Baseline (end of week 8) to Week 14

  5. Change From End of Phase A (Week 8) to End of Phase B (Week 14) in the Hamilton Depression Rating Scale 17-item Version (HAM-D17) Total Score.

    The HAM-D17 was utilized as a secondary assessment of a participants level of depression. The HAM-D (17-Item) consisted of 17 items. Eight items were rated on a 0 to 2 scale (items 4, 5, 6, 12, 13, 14, 16 and 17), while nine items (items 1, 2, 3, 7, 8, 9, 10, 11, and 15) were rated on a 0 to 4 scale (twice the weight of the other items). For all of these items, 0 was the "best" rating and the highest score (2 or 4) was the "worst" rating. The possible total scores were from 0 to 52.

    Time frame: Baseline (end of week 8) to Week 14

  6. Clinical Global Impression- Improvement Scale (CGI-I) Score by Study Week in Phase B Relative to End of Phase A.

    The efficacy of study medication was rated for each participant using the CGI-I. The study physician would rate the participants total improvement whether or not it is due entirely to drug treatment. Response choices included: 0 = not assessed, 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, and 7 = very much worse.

    Time frame: Baseline (end of week 8) to Week 14

  7. Number of Participants With MADRS Response During Phase B Relative to the End of Phase A (Week 8) Visit.

    A MADRS response was defined as \>=50 percent reduction in MADRS Total Score from end of Phase A (Week 8 visit). The MADRS consisted of 10 items, all rated on a 0 to 6 scale with 0 being the "best" rating and 6 being the "worst" rating. The MADRS Total Score is the sum of ratings for all 10 items; therefore, possible total scores range from 0 to 60. The MADRS total score were to be unevaluable if less than 8 of the 10 items were recorded. If 8 or 9 of the 10 items were recorded, the MADRS total score was the mean of the recorded items multiplied by 10 and then rounded of to the first decimal place.

    Time frame: Baseline (end of week 8) to Week 14

  8. Number of Participants With MADRS Remission During Phase B Relative to the End of Phase A (Week 8) Visit.

    A MADRS remission was defined as MADRS Total Score =\< 10 and \>= 50 percent reduction in MADRS Total Score from end of Phase A (Week 8 visit). The MADRS consisted of 10 items, all rated on a 0 to 6 scale with 0 being the "best" rating and 6 being the "worst" rating. The MADRS Total Score is the sum of ratings for all 10 items; therefore, possible total scores range from 0 to 60. The MADRS total score were to be unevaluable if less than 8 of the 10 items were recorded. If 8 or 9 of the 10 items were recorded, the MADRS total score was the mean of the recorded items multiplied by 10 and then rounded of to the first decimal place.

    Time frame: Baseline (end of week 8) to Week 14

  9. Number of Participants With CGI-Improvement Response During Phase B Relative to the End of Phase A (Week 8).

    CGI-I Response was defined as a CGI-I score of 1 (very much improved) or 2 (much improved).

    Time frame: Baseline (end of week 8) to Week 14

07

Results

Posted Nov 2, 2015

Participant flow

This trial was conducted in the United States in 773 participants at 44 centers. A total of 1226 participants were screened, 773 participants were enrolled in Phase A, and 769 were treated in Phase A. Of the 623 participants who completed Phase A, 372 participants were randomized in to Phase B.

Phase A
Participant flow — Phase A
MilestonePhase ABrexiprazolePlaceboPhase A+
Started769000
Completed623000
Not completed146000
Withdrew: Lost to follow-up22000
Withdrew: Adverse event32000
Withdrew: Met withdrawal criteria26000
Withdrew: Physician decision10000
Withdrew: Withdrawal by subject29000
Withdrew: Protocol deviation27000
Phase B
Participant flow — Phase B
MilestonePhase ABrexiprazolePlaceboPhase A+
Started01851870
Completed01671710
Not completed018160
Withdrew: Lost to follow-up0230
Withdrew: Adverse event0920
Withdrew: Met withdrawal criteria0210
Withdrew: Physician decision0110
Withdrew: Withdrawal by subject0050
Withdrew: Protocol deviation0340
Withdrew: Lack of efficacy0100
Phase A+
Participant flow — Phase A+
MilestonePhase ABrexiprazolePlaceboPhase A+
Started000251
Completed000230
Not completed00021
Withdrew: Lost to follow-up0008
Withdrew: Adverse event0004
Withdrew: Met withdrawal criteria0002
Withdrew: Withdrawal by subject0007

Outcome measures

PrimaryChange From the End of Phase A (Week 8 Visit) to the End of Phase B (Week 14 Visit) in the Montgomery Asberg Depression Rating Scale (MADRS) Total Score.

The MADRS was utilized as the primary efficacy assessment of a participants level of depression. The MADRS consisted of 10 items, all rated on a 0 to 6 scale with 0 being the "best" rating and 6 being the "worst" rating. The MADRS Total Score is the sum of ratings for all 10 items; therefore, possible total scores range from 0 to 60. The MADRS total score were to be unevaluable if less than 8 of the 10 items were recorded. If 8 or 9 of the 10 items were recorded, the MADRS total score was the mean of the recorded items multiplied by 10 and then rounded of to the first decimal place.

Time frame:
Baseline (end of week 8) to Week 14
Reported as:
Least squares mean · Units on a scale
Change From the End of Phase A (Week 8 Visit) to the End of Phase B (Week 14 Visit) in the Montgomery Asberg Depression Rating Scale (MADRS) Total Score.
Units on a scaleBrexpiprazolePlacebo
Change From the End of Phase A (Week 8 Visit) to the End of Phase B (Week 14 Visit) in the Montgomery Asberg Depression Rating Scale (MADRS) Total Score.-8.20 ± 0.62-7.02 ± 0.62
Statistical analysis
  • Brexpiprazole vs Placebo · ANCOVA · p = 0.1416 (ANCOVA model, with treatment and study center as main effects and Week 8 value as convariate, is used for change from Week 8 comparisons.) · Mean difference (final values): -1.18 · 95% CI -2.75 to 0.39Treatment difference = difference in adjusted mean change: brexpiprazole - placebo.
SecondaryChange From End of Phase A (Week 8) to Phase B in Sheehan Disability Scale (SDS) Score.

The SDS was a self-rated instrument used to measure the effect of the participants symptoms on work/school, social life, and family/home responsibilities. For each of the three items, scores ranged from 0 through 10. The number most representative of how much each area was disrupted by symptoms was marked along the line from 0= not at all, to 10= extremely. Scores of 5 and above are associated with significant functional impairment. The SDS total score ranges from 0 to 30, with higher values indicating greater disruption in the participant's work/social/family life. For the work/school item, no response was to be entered if the participant did not work or go to school for reasons unrelated to the disorder and a response therefore not being applicable. The Mean SDS score were calculated over the three item scores. All three item scores were needed to be available with the exception of the work/school item score when this item was not applicable.

Time frame:
Baseline (end of week 8) to Week 14
Reported as:
Least squares mean · Units on a scale
Change From End of Phase A (Week 8) to Phase B in Sheehan Disability Scale (SDS) Score.
Units on a scaleBrexpiprazolePlacebo
Change From End of Phase A (Week 8) to Phase B in Sheehan Disability Scale (SDS) Score.-0.91 ± 0.19-0.69 ± 0.19
Statistical analysis
  • Brexpiprazole vs Placebo · ANCOVA · p = 0.3778 (ANCOVA model, with treatment and study center as main effects and Week 8 value as covariate, is used for change from Week 8 comparisons.) · Mean difference (final values): -0.22 · 95% CI -0.69 to 0.26Treatment difference = difference in adjusted mean change: brexpiprazole - placebo.
SecondaryChange From End of Phase A (Week 8 Visit) in MADRS Total Score for Every Trial Week Visit in Phase B.

The MADRS was utilized as the primary efficacy assessment of a participants level of depression. The MADRS consisted of 10 items, all rated on a 0 to 6 scale with 0 being the "best" rating and 6 being the "worst" rating. The MADRS Total Score is the sum of ratings for all 10 items; therefore, possible total scores range from 0 to 60. The MADRS total score were to be unevaluable if less than 8 of the 10 items were recorded. If 8 or 9 of the 10 items were recorded, the MADRS total score was the mean of the recorded items multiplied by 10 and then rounded of to the first decimal place.

Time frame:
Baseline (end of week 8) to Week 14
Reported as:
Least squares mean · Units on a scale
Change From End of Phase A (Week 8 Visit) in MADRS Total Score for Every Trial Week Visit in Phase B.
Units on a scaleBrexpiprazolePlacebo
Week 9 (N= 181, 180)-3.30 ± 0.42-1.99 ± 0.42
Week 10 (N= 184, 181)-5.92 ± 0.50-4.01 ± 0.50
Week 11 (N= 184, 181)-7.23 ± 0.57-5.22 ± 0.57
Week 12 (N= 184, 181)-8.42 ± 0.59-6.21 ± 0.59
Week 13 (N= 184, 181)-9.00 ± 0.59-7.18 ± 0.59
Week 14 (N= 184, 181)-8.20 ± 0.62-7.02 ± 0.62
Statistical analysis
  • Brexpiprazole vs Placebo · ANCOVA · p = 0.0162 (ANCOVA model, with treatment and trial center as main effects and Week 8 value as covariate, was used for change from Week 8 comparisons.) · Mean difference (final values): -1.31 · 95% CI -2.38 to -0.24Treatment difference = difference in adjusted mean change: brexpiprazole - placebo.
  • Brexpiprazole vs Placebo · ANCOVA · p = 0.0031 (ANCOVA model, with treatment and trial center as main effects and Week 8 value as covariate, was used for change from Week 8 comparisons.) · Mean difference (final values): -1.90 · 95% CI -3.15 to -0.65Treatment difference = difference in adjusted mean change: brexpiprazole - placebo.
  • Brexpiprazole vs Placebo · ANCOVA · p = 0.0061 (ANCOVA model, with treatment and trial center as main effects and Week 8 value as covariate, was used for change from Week 8 comparisons.) · Mean difference (final values): -2.01 · 95% CI -3.44 to -0.58Treatment difference = difference in adjusted mean change: brexpiprazole - placebo.
  • Brexpiprazole vs Placebo · ANCOVA · p = 0.0038 (ANCOVA model, with treatment and trial center as main effects and Week 8 value as covariate, was used for change from Week 8 comparisons.) · Mean difference (final values): -2.21 · 95% CI -3.69 to -0.72Treatment difference = difference in adjusted mean change: brexpiprazole - placebo.
  • Brexpiprazole vs Placebo · ANCOVA · p = 0.0174 (ANCOVA model, with treatment and trial center as main effects and Week 8 value as covariate, was used for change from Week 8 comparisons.) · Mean difference (final values): -1.82 · 95% CI -3.32 to -0.32Treatment difference = difference in adjusted mean change: brexpiprazole - placebo.
  • Brexpiprazole vs Placebo · ANCOVA · p = 0.1416 (ANCOVA model, with treatment and trial center as main effects and Week 8 value as covariate, was used for change from Week 8 comparisons.) · Mean difference (final values): -1.18 · 95% CI -2.75 to 0.39Treatment difference = difference in adjusted mean change: brexpiprazole - placebo.
SecondaryChange From End of Phase A (Week 8 Visit) to Phase B by Study Week in Clinical Global Impression- Severity Illness Scale (CGI-S) Score.

The severity of illness for each participant was rated using the CGI-S. To perform this assessment, the investigator had to answer the following question: "Considering your total clinical experience with this particular population, how mentally ill is the participant at this time?" Response choices included: 0 = not assessed; 1 = normal, not at all ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill participants.

Time frame:
Baseline (end of week 8) to Week 14
Reported as:
Least squares mean · Units on a scale
Change From End of Phase A (Week 8 Visit) to Phase B by Study Week in Clinical Global Impression- Severity Illness Scale (CGI-S) Score.
Units on a scaleBrexpiprazolePlacebo
Week 9 (N= 181, 180)-0.29 ± 0.05-0.20 ± 0.05
Week 10 (N= 184, 181)-0.58 ± 0.06-0.44 ± 0.06
Week 11 (N= 184, 181)-0.76 ± 0.07-0.59 ± 0.07
Week 12 (N= 184, 181)-0.94 ± 0.07-0.68 ± 0.07
Week 13 (N= 184, 181)-1.00 ± 0.08-0.81 ± 0.08
Week 14 (N= 184, 181)-0.95 ± 0.08-0.85 ± 0.08
Statistical analysis
  • Brexpiprazole vs Placebo · ANCOVA · p = 0.1481 (ANCOVA model, with treatment and study center as main effects and Week 8 value as covariate, is used for change from Week 8 comparisons.) · Mean difference (final values): -0.09 · 95% CI -0.21 to 0.03Treatment difference = difference in adjusted mean change: brexpiprazole - placebo.
  • Brexpiprazole vs Placebo · ANCOVA · p = 0.0691 (ANCOVA model, with treatment and trial center as main effects and Week 8 value as covariate, was used for change from Week 8 comparisons.) · Mean difference (final values): -0.14 · 95% CI -0.28 to 0.01Treatment difference = difference in adjusted mean change: brexpiprazole - placebo.
  • Brexpiprazole vs Placebo · ANCOVA · p = 0.0457 (ANCOVA model, with treatment and trial center as main effects and Week 8 value as covariate, was used for change from Week 8 comparisons.) · Mean difference (final values): -0.17 · 95% CI -0.35 to -0.00Treatment difference = difference in adjusted mean change: brexpiprazole - placebo.
  • Brexpiprazole vs Placebo · ANCOVA · p = 0.0061 (ANCOVA model, with treatment and trial center as main effects and Week 8 value as covariate, was used for change from Week 8 comparisons.) · Mean difference (final values): -0.26 · 95% CI -0.45 to -0.08Treatment difference = difference in adjusted mean change: brexpiprazole - placebo.
  • Brexpiprazole vs Placebo · ANCOVA · p = 0.0572 (ANCOVA model, with treatment and trial center as main effects and Week 8 value as covariate, was used for change from Week 8 comparisons.) · Mean difference (final values): -0.19 · 95% CI -0.38 to 0.01Treatment difference = difference in adjusted mean change: brexpiprazole - placebo.
  • Brexpiprazole vs Placebo · ANCOVA · p = 0.3318 (ANCOVA model, with treatment and trial center as main effects and Week 8 value as covariate, was used for change from Week 8 comparisons.) · Mean difference (final values): -0.10 · 95% CI -0.29 to 0.10Treatment difference = difference in adjusted mean change: brexpiprazole - placebo.
SecondaryChange From End of Phase A (Week 8 Visit) to Phase B by Study Week in Inventory of Depressive Symptomatology (Self-Report) (IDS-SR) Total Score.

The IDS-SR was a 30-item self-report measure, that was used to assess core diagnostic depressive symptoms as well as atypical and melancholic symptom features of major depressive disorder (MDD). For individual items, the scores range from 0 to 3. The IDS-SR are scored by summing responses to 28 of the 30 items to obtain a total score ranging from 0 to 84, higher values indicate greater disruption in the depressive symptoms.

Time frame:
Baseline (end of week 8) to Week 14
Reported as:
Least squares mean · Units on a scale
Change From End of Phase A (Week 8 Visit) to Phase B by Study Week in Inventory of Depressive Symptomatology (Self-Report) (IDS-SR) Total Score.
Units on a scaleBrexpiprazolePlacebo
Week 9 (N= 181, 179)-1.65 ± 0.54-1.99 ± 0.53
Week 10 (N= 184, 181)-2.91 ± 0.60-2.93 ± 0.60
Week 11 (N= 184, 181)-3.92 ± 0.68-3.64 ± 0.68
Week 12 (N= 184, 181)-4.82 ± 0.74-4.76 ± 0.74
Week 13 (N= 184, 181)-5.60 ± 0.75-5.59 ± 0.75
Week 14 (N= 184, 181)-5.70 ± 0.80-5.84 ± 0.80
Statistical analysis
  • Brexpiprazole vs Placebo · ANCOVA · p = 0.6272 (ANCOVA model, with treatment and trial center as main effects and Week 8 value as covariate, was used for change from Week 8 comparisons.) · Mean difference (final values): 0.34 · 95% CI -1.02 to 1.69Treatment difference = difference in adjusted mean change: brexpiprazole - placebo.
  • Brexpiprazole vs Placebo · ANCOVA · p = 0.9697 (ANCOVA model, with treatment and trial center as main effects and Week 8 value as covariate, was used for change from Week 8 comparisons.) · Mean difference (final values): 0.03 · 95% CI -1.48 to 1.54Treatment difference = difference in adjusted mean change: brexpiprazole - placebo
  • Brexpiprazole vs Placebo · ANCOVA · p = 0.7490 (ANCOVA model, with treatment and trial center as main effects and Week 8 value as covariate, was used for change from Week 8 comparisons.) · Mean difference (final values): -0.28 · 95% CI -2.00 to 1.44Treatment difference = difference in adjusted mean change: brexpiprazole - placebo.
  • Brexpiprazole vs Placebo · ANCOVA · p = 0.9459 (ANCOVA model, with treatment and trial center as main effects and Week 8 value as covariate, was used for change from Week 8 comparisons.) · Mean difference (final values): 0.06 · 95% CI -1.94 to 1.81Treatment difference = difference in adjusted mean change: brexpiprazole - placebo.
  • Brexpiprazole vs Placebo · ANCOVA · p = 0.9893 (ANCOVA model, with treatment and trial center as main effects and Week 8 value as covariate, was used for change from Week 8 comparisons.) · Mean difference (final values): -0.01 · 95% CI -1.91 to 1.88Treatment difference = difference in adjusted mean change: brexpiprazole - placebo.
  • Brexpiprazole vs Placebo · ANCOVA · p = 0.8918 (ANCOVA model, with treatment and trial center as main effects and Week 8 value as covariate, was used for change from Week 8 comparisons.) · Mean difference (final values): 0.14 · 95% CI -1.89 to 2.17Treatment difference = difference in adjusted mean change: brexpiprazole - placebo.
SecondaryChange From End of Phase A (Week 8) to End of Phase B (Week 14) in the Hamilton Depression Rating Scale 17-item Version (HAM-D17) Total Score.

The HAM-D17 was utilized as a secondary assessment of a participants level of depression. The HAM-D (17-Item) consisted of 17 items. Eight items were rated on a 0 to 2 scale (items 4, 5, 6, 12, 13, 14, 16 and 17), while nine items (items 1, 2, 3, 7, 8, 9, 10, 11, and 15) were rated on a 0 to 4 scale (twice the weight of the other items). For all of these items, 0 was the "best" rating and the highest score (2 or 4) was the "worst" rating. The possible total scores were from 0 to 52.

Time frame:
Baseline (end of week 8) to Week 14
Reported as:
Least squares mean · Units on a scale
Change From End of Phase A (Week 8) to End of Phase B (Week 14) in the Hamilton Depression Rating Scale 17-item Version (HAM-D17) Total Score.
Units on a scaleBrexpiprazolePlacebo
Change From End of Phase A (Week 8) to End of Phase B (Week 14) in the Hamilton Depression Rating Scale 17-item Version (HAM-D17) Total Score.-5.98 ± 0.45-5.40 ± 0.45
Statistical analysis
  • Brexpiprazole vs Placebo · ANCOVA · p = 0.3247 (ANCOVA model, with treatment and trial center as main effects and Week 8 value as covariate, was used for change from Week 8 comparisons.) · Mean difference (final values): -0.57 · 95% CI -1.71 to 0.57Treatment difference = difference in adjusted mean change: brexpiprazole - placebo.
SecondaryClinical Global Impression- Improvement Scale (CGI-I) Score by Study Week in Phase B Relative to End of Phase A.

The efficacy of study medication was rated for each participant using the CGI-I. The study physician would rate the participants total improvement whether or not it is due entirely to drug treatment. Response choices included: 0 = not assessed, 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, and 7 = very much worse.

Time frame:
Baseline (end of week 8) to Week 14
Reported as:
Mean · Units on a scale
Clinical Global Impression- Improvement Scale (CGI-I) Score by Study Week in Phase B Relative to End of Phase A.
Units on a scaleBrexpiprazolePlacebo
Week 9 (N= 181, 179)3.33 ± 0.823.37 ± 0.74
Week 10 (N= 184, 180)3.03 ± 0.973.15 ± 0.84
Week 11 (N= 184, 180)3.00 ± 1.083.02 ± 0.99
Week 12 (N= 184, 180)2.63 ± 1.122.91 ± 1.02
Week 13 (N= 184, 180)2.60 ± 1.142.80 ± 1.02
Week 14 (N= 184, 181)2.68 ± 1.182.78 ± 1.07
Statistical analysis
  • Brexpiprazole vs Placebo · Cochran-Mantel-Haenszel · p = 0.5616 (Cohran-Mantel-Haenszel (CMH) row mean scores differ test controlling for study center.)Treatment difference = difference in adjusted mean: brexpiprazole - placebo.
  • Brexpiprazole vs Placebo · Cochran-Mantel-Haenszel · p = 0.1900 (CMH row mean scores differ test controlling for study center.)Treatment difference = difference in adjusted mean change: brexpiprazole - placebo.
  • Brexpiprazole vs Placebo · Cochran-Mantel-Haenszel · p = 0.0501 (CMH row mean scores differ test controlling for study center.)Treatment difference = difference in adjusted mean change: brexpiprazole - placebo.
  • Brexpiprazole vs Placebo · Cochran-Mantel-Haenszel · p = 0.0137 (CMH row mean scores differ test controlling for study center.)Treatment difference = difference in adjusted mean change: brexpiprazole - placebo.
  • Brexpiprazole vs Placebo · Cochran-Mantel-Haenszel · p = 0.0711 (CMH row mean scores differ test controlling for study center.)Treatment difference = difference in adjusted mean change: brexpiprazole - placebo.
  • Brexpiprazole vs Placebo · Cochran-Mantel-Haenszel · p = 0.3438 (CMH row mean scores differ test controlling for study center.)Treatment difference = difference in adjusted mean change: brexpiprazole - placebo.
SecondaryNumber of Participants With MADRS Response During Phase B Relative to the End of Phase A (Week 8) Visit.

A MADRS response was defined as \>=50 percent reduction in MADRS Total Score from end of Phase A (Week 8 visit). The MADRS consisted of 10 items, all rated on a 0 to 6 scale with 0 being the "best" rating and 6 being the "worst" rating. The MADRS Total Score is the sum of ratings for all 10 items; therefore, possible total scores range from 0 to 60. The MADRS total score were to be unevaluable if less than 8 of the 10 items were recorded. If 8 or 9 of the 10 items were recorded, the MADRS total score was the mean of the recorded items multiplied by 10 and then rounded of to the first decimal place.

Time frame:
Baseline (end of week 8) to Week 14
Reported as:
Number · participants
Number of Participants With MADRS Response During Phase B Relative to the End of Phase A (Week 8) Visit.
participantsBrexpiprazolePlacebo
Week 9 (N= 181, 180)114
Week 10 (N= 184, 181)2916
Week 11 (N= 184, 181)4126
Week 12 (N= 184, 181)5628
Week 13 (N= 184, 181)5533
Week 14 (N= 184, 181)5536
Statistical analysis
  • Brexpiprazole vs Placebo · Cochran-Mantel-Haenszel · p = 0.0679 · Ratio of response rate: 2.79 · 95% CI 0.88 to 8.81The CMH general association test controlling for trial center.
  • Brexpiprazole vs Placebo · Cochran-Mantel-Haenszel · p = 0.0360 · Ratio of response rate: 1.78 · 95% CI 1.01 to 3.14The CMH general association test controlling for trial center.
  • Brexpiprazole vs Placebo · Cochran-Mantel-Haenszel · p = 0.0521 · Ratio of response rate: 1.53 · 95% CI 0.99 to 2.35The CMH general association test controlling for trial center.
  • Brexpiprazole vs Placebo · Cochran-Mantel-Haenszel · p = 0.0008 · Ratio of response rate: 1.93 · 95% CI 1.31 to 2.86The CMH general association test controlling for trial center.
  • Brexpiprazole vs Placebo · Cochran-Mantel-Haenszel · p = 0.0074 · Ratio of response rate: 1.64 · 95% CI 1.14 to 2.38The CMH general association test controlling for trial center.
  • Brexpiprazole vs Placebo · Cochran-Mantel-Haenszel · p = 0.0339 · Ratio of response rate: 1.47 · 95% CI 1.03 to 2.08The CMH general association test controlling for trial center.
SecondaryNumber of Participants With MADRS Remission During Phase B Relative to the End of Phase A (Week 8) Visit.

A MADRS remission was defined as MADRS Total Score =\< 10 and \>= 50 percent reduction in MADRS Total Score from end of Phase A (Week 8 visit). The MADRS consisted of 10 items, all rated on a 0 to 6 scale with 0 being the "best" rating and 6 being the "worst" rating. The MADRS Total Score is the sum of ratings for all 10 items; therefore, possible total scores range from 0 to 60. The MADRS total score were to be unevaluable if less than 8 of the 10 items were recorded. If 8 or 9 of the 10 items were recorded, the MADRS total score was the mean of the recorded items multiplied by 10 and then rounded of to the first decimal place.

Time frame:
Baseline (end of week 8) to Week 14
Reported as:
Number · participants
Number of Participants With MADRS Remission During Phase B Relative to the End of Phase A (Week 8) Visit.
participantsBrexpiprazolePlacebo
Week 9 (N= 181, 180)73
Week 10 (N= 184, 181)157
Week 11 (N= 184, 181)3118
Week 12 (N= 184, 181)4219
Week 13 (N= 184, 181)4625
Week 14 (N= 184, 181)4827
Statistical analysis
  • Brexpiprazole vs Placebo · Cochran-Mantel-Haenszel · p = 0.2404 · Ratio of remission rate: 2.27 · 95% CI 0.55 to 9.30The CMH general association test controlling for trial center.
  • Brexpiprazole vs Placebo · Cochran-Mantel-Haenszel · p = 0.0983 · Ratio of remission rate: 2.04 · 95% CI 0.83 to 4.98The CMH general association test controlling for trial center.
  • Brexpiprazole vs Placebo · Cochran-Mantel-Haenszel · p = 0.0496 · Ratio of remission rate: 1.67 · 95% CI 0.99 to 2.82The CMH general association test controlling for trial center.
  • Brexpiprazole vs Placebo · Cochran-Mantel-Haenszel · p = 0.0019 · Ratio of remission rate: 2.12 · 95% CI 1.31 to 3.46The CMH general association test controlling for trial center.
  • Brexpiprazole vs Placebo · Cochran-Mantel-Haenszel · p = 0.0068 · Ratio of response rate: 1.77 · 95% CI 1.17 to 2.67The CMH general association test controlling for trial center.
  • Brexpiprazole vs Placebo · Cochran-Mantel-Haenszel · p = 0.0089 (The CMH general association test controlling for trial center.) · Ratio of remission rate: 1.71 · 95% CI 1.14 to 2.57Treatment difference = difference in adjusted mean change: brexpiprazole - placebo.
SecondaryNumber of Participants With CGI-Improvement Response During Phase B Relative to the End of Phase A (Week 8).

CGI-I Response was defined as a CGI-I score of 1 (very much improved) or 2 (much improved).

Time frame:
Baseline (end of week 8) to Week 14
Reported as:
Number · participants
Number of Participants With CGI-Improvement Response During Phase B Relative to the End of Phase A (Week 8).
participantsBrexpiprazolePlacebo
Week 9 (N= 181, 179)2319
Week 10 (N= 184, 180)4739
Week 11 (N= 184, 180)7351
Week 12 (N= 184, 181)8863
Week 13 (N= 184, 181)9070
Week 14 (N= 184, 181)8472
Statistical analysis
  • Brexpiprazole vs Placebo · Cochran-Mantel-Haenszel · p = 0.4605 · Ratio of response rate: 1.23 · 95% CI 0.70 to 2.18CMH general association test controlling for study center.
  • Brexpiprazole vs Placebo · Cochran-Mantel-Haenszel · p = 0.3267 · Ratio of response rate: 1.20 · 95% CI 0.83 to 1.72CMH general association test controlling for study center.
  • Brexpiprazole vs Placebo · Cochran-Mantel-Haenszel · p = 0.0230 · Ratio of response rate: 1.37 · 95% CI 1.05 to 1.80CMH general association test controlling for study center.
  • Brexpiprazole vs Placebo · Cochran-Mantel-Haenszel · p = 0.0105 · Ratio of response rate: 1.36 · 95% CI 1.08 to 1.71CMH general association test controlling for study center.
  • Brexpiprazole vs Placebo · Cochran-Mantel-Haenszel · p = 0.0417 · Ratio of response rate: 1.26 · 95% CI 1.01 to 1.58CMH general association test controlling for study center.
  • Brexpiprazole vs Placebo · Cochran-Mantel-Haenszel · p = 0.2345 (CMH general association test controlling for study center.) · Ratio of response rate: 1.15 · 95% CI 0.91 to 1.44Treatment difference = difference in adjusted mean change: brexpiprazole - placebo.

Adverse events

Collected over AEs were recorded from the time the participant entered Phase B, throughout the 6-week treatment period (Week 9 to Week 14) and until follow-up at 30 days after the last dose of medication.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Brexpiprazole—0/185 (0%)90/185 (48.6%)
Placebo—3/187 (1.6%)63/187 (33.7%)
Most frequent serious events
Most frequent serious events
EventBrexpiprazolePlacebo
Sinus bradycardiaCardiac disorders0/1851/187
DepressionPsychiatric disorders0/1851/187
HypotensionVascular disorders0/1851/187
Subclavian vein thrombosisVascular disorders0/1851/187
Most frequent other events
Most frequent other events
EventBrexpiprazolePlacebo
AkathisiaNervous system disorders22/1859/187
Weight increasedInvestigations21/1855/187
InsomniaPsychiatric disorders17/1856/187
HeadacheNervous system disorders9/18516/187
FatigueGeneral disorders14/1858/187
Increased appetiteMetabolism and nutrition disorders14/1853/187
NasopharyngitisInfections and infestations12/1855/187
ConstipationGastrointestinal disorders11/1854/187
DiarrhoeaGastrointestinal disorders10/18510/187
Upper respiratory tract infectionInfections and infestations9/18510/187

Baseline characteristics

Age, Continuous
Age, Continuous(Years)BrexpiprazolePlaceboTotal
Mean44.7 ± 11.742.4 ± 11.743.5 ± 11.8
Sex: Female, Male
Sex: Female, Male(Participants)BrexpiprazolePlaceboTotal
Female123130253
Male6257119
08

Study locations

43 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35294, United States
  • Pacific Clinical Research Medical Group
    Arcadia, California 91007, United States
  • Southwestern Research
    Beverly Hills, California 90210, United States
  • Excell Research
    Oceanside, California 92056, United States
  • Affiliated Research Institute
    San Diego, California 92108, United States
  • Neuropsychiatric Research Center of Orange County
    Santa Ana, California 92782, United States
  • California Neuroscience Research Medical Group, Inc.
    Sherman Oaks, California 91403, United States
  • CNS Clinical Research Group
    Coral Springs, Florida 33067, United States
  • Gulfcoast Clinical Research Center
    Fort Myers, Florida 33912, United States
  • Clinical Neuroscience Solutions, Inc.
    Jacksonville, Florida 32216, United States
  • Scientific Clinical Research, Inc.
    North Miami, Florida 33161, United States
  • Clinical Neuroscience Solutions, Inc.
    Orlando, Florida 32806, United States
  • Comprehensive NeuroScience, Inc.
    Atlanta, Georgia 30328, United States
  • Carman Research
    Smyrna, Georgia 30080, United States
  • Goldpoint Clinical Research, LLC
    Indianapolis, Indiana 46260, United States
  • Vince and Associates Clinical Research
    Overland Park, Kansas 66212, United States
  • Clinical InSights
    Glen Burnie, Maryland 21061, United States
  • Pharmasite Research, Inc.
    Pikesville, Maryland 21208, United States
  • MSU/Institute for Health Studies
    East Lansing, Michigan 48824, United States
  • Center for Emotional Fitness
    Cherry Hill, New Jersey 08002, United States
  • Neurobehavioral Research, Inc.
    Cedarhurst, New York 11515, United States
  • Eastside Comprehensive Medical Center
    New York, New York 10021, United States
  • Medical & Behavioral Health Research, PC
    New York, New York 10023, United States
  • Finger Lakes Clinical Research
    Rochester, New York 14618, United States
  • Richmond Behavioral Associates
    Staten Island, New York 10312, United States
  • Northcoast Clinical Trials
    Beachwood, Ohio 44122, United States
  • Patient Priority Clinical sites, LLC
    Cincinnati, Ohio 45242, United States
  • Midwest Clinical Research Center
    Dayton, Ohio 45408, United States
  • IPS Research Company
    Oklahoma City, Oklahoma 73103, United States
  • Summit Research Network (Oregon), LLC
    Portland, Oregon 97210, United States
  • City Line Avenue Family Practice
    Bala-Cynwyd, Pennsylvania 19004, United States
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • Lincoln Research
    Lincoln, Rhode Island 02865, United States
  • Clinical NeuroScience Solutions, Inc.
    Memphis, Tennessee 38119, United States
  • FutureSearch Trials
    Austin, Texas 78756, United States
  • FutureSearch Trials of Dallas
    Dallas, Texas 75231, United States
  • Clinical Trials of Texas
    San Antonio, Texas 78229, United States
  • Radiant Research
    Salt Lake City, Utah 84107, United States
  • Psychiatric Alliance of The Blue Ridge
    Charlottesville, Virginia 22903, United States
  • NeuroScience, Inc.
    Herndon, Virginia 20170, United States
  • Northwest Clinical Research Center
    Bellevue, Washington 98007, United States
  • Summit Research Network (Seattle), LLC
    Seattle, Washington 98104, United States
  • Northbrooke Research Center
    Brown Deer, Wisconsin 53223, United States
09

References and documents

Publications

  • Hobart M, Zhang P, Weiss C, Meehan SR, Eriksson H. Adjunctive Brexpiprazole and Functioning in Major Depressive Disorder: A Pooled Analysis of Six Randomized Studies Using the Sheehan Disability Scale. Int J Neuropsychopharmacol. 2019 Mar 1;22(3):173-179. doi: 10.1093/ijnp/pyy095. PubMed 30508090 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2010, a primary completion of Oct 2011 and a completion of Nov 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2015, 4 years 1 month after primary completion. A results delay was requested in Nov 2012.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 15, 2010
First posted
Jan 20, 2010
Start
Mar 2010
Primary completionActual
Oct 2011
CompletionActual
Nov 2011
Results delay requested
Nov 1, 2012
Results first posted
Nov 2, 2015
Last update
Nov 2, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 2, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01052077
Responsible party
Sponsor
First posted
Jan 20, 2010
Start date
Mar 2010
Primary completion
Oct 2011
Completion
Nov 2011
Results posted
Nov 2, 2015
Last update
Nov 2, 2015
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brexpiprazole

Start the discussion